Connection

Lee Chao to Tissue Kallikreins

Back to Details
This is a "connection" page, showing publications Lee Chao has written about Tissue Kallikreins.
Lee Chao
Connection Strength
5.064
Tissue Kallikreins
  1. Tissue kallikrein-kinin therapy in hypertension and organ damage. Prog Drug Res. 2014; 69:37-57.
    View in: PubMed
    Score: 0.424
  2. Tissue kallikrein is related to the severity of coronary artery disease. Clin Chim Acta. 2013 Aug 23; 423:90-8.
    View in: PubMed
    Score: 0.404
  3. Tissue kallikrein-modified human endothelial progenitor cell implantation improves cardiac function via enhanced activation of akt and increased angiogenesis. Lab Invest. 2013 May; 93(5):577-91.
    View in: PubMed
    Score: 0.401
  4. Tissue kallikrein promotes cardiac neovascularization by enhancing endothelial progenitor cell functional capacity. Hum Gene Ther. 2012 Aug; 23(8):859-70.
    View in: PubMed
    Score: 0.377
  5. Tissue kallikrein in cardiovascular, cerebrovascular and renal diseases and skin wound healing. Biol Chem. 2010 Apr; 391(4):345-55.
    View in: PubMed
    Score: 0.327
  6. Tissue kallikrein elicits cardioprotection by direct kinin b2 receptor activation independent of kinin formation. Hypertension. 2008 Oct; 52(4):715-20.
    View in: PubMed
    Score: 0.293
  7. The tissue kallikrein-kinin system protects against cardiovascular and renal diseases and ischemic stroke independently of blood pressure reduction. Biol Chem. 2006 Jun; 387(6):665-75.
    View in: PubMed
    Score: 0.250
  8. Experimental therapy with tissue kallikrein against cerebral ischemia. Front Biosci. 2006 May 01; 11:1323-7.
    View in: PubMed
    Score: 0.249
  9. Kallikrein-kinin in stroke, cardiovascular and renal disease. Exp Physiol. 2005 May; 90(3):291-8.
    View in: PubMed
    Score: 0.228
  10. Adenovirus-mediated kallikrein gene delivery attenuates hypertension and protects against renal injury in deoxycorticosterone-salt rats. Immunopharmacology. 1999 Oct 15; 44(1-2):57-65.
    View in: PubMed
    Score: 0.158
  11. Kallistatin ameliorates influenza virus pathogenesis by inhibition of kallikrein-related peptidase 1-mediated cleavage of viral hemagglutinin. Antimicrob Agents Chemother. 2015 Sep; 59(9):5619-30.
    View in: PubMed
    Score: 0.118
  12. Tissue kallikrein-modified mesenchymal stem cells provide enhanced protection against ischemic cardiac injury after myocardial infarction. Circ J. 2013; 77(8):2134-44.
    View in: PubMed
    Score: 0.101
  13. Tissue kallikrein promotes prostate cancer cell migration and invasion via a protease-activated receptor-1-dependent signaling pathway. Biol Chem. 2010 Jul; 391(7):803-12.
    View in: PubMed
    Score: 0.083
  14. Blockade of endogenous tissue kallikrein aggravates renal injury by enhancing oxidative stress and inhibiting matrix degradation. Am J Physiol Renal Physiol. 2010 Apr; 298(4):F1033-40.
    View in: PubMed
    Score: 0.081
  15. A novel signaling pathway of tissue kallikrein in promoting keratinocyte migration: activation of proteinase-activated receptor 1 and epidermal growth factor receptor. Exp Cell Res. 2010 Feb 01; 316(3):376-89.
    View in: PubMed
    Score: 0.079
  16. Tissue kallikrein promotes neovascularization and improves cardiac function by the Akt-glycogen synthase kinase-3beta pathway. Cardiovasc Res. 2008 Dec 01; 80(3):354-64.
    View in: PubMed
    Score: 0.073
  17. Kallikrein-modified mesenchymal stem cell implantation provides enhanced protection against acute ischemic kidney injury by inhibiting apoptosis and inflammation. Hum Gene Ther. 2008 Aug; 19(8):807-19.
    View in: PubMed
    Score: 0.073
  18. Tissue kallikrein and kinin infusion promotes neovascularization in limb ischemia. Biol Chem. 2008 Jun; 389(6):725-30.
    View in: PubMed
    Score: 0.072
  19. Role of tissue kallikrein in prevention and recovery of gentamicin-induced renal injury. Toxicol Sci. 2008 Apr; 102(2):433-43.
    View in: PubMed
    Score: 0.070
  20. Tissue kallikrein and kinin infusion rescues failing myocardium after myocardial infarction. J Card Fail. 2007 Sep; 13(7):588-96.
    View in: PubMed
    Score: 0.068
  21. Tissue kallikrein reverses insulin resistance and attenuates nephropathy in diabetic rats by activation of phosphatidylinositol 3-kinase/protein kinase B and adenosine 5'-monophosphate-activated protein kinase signaling pathways. Endocrinology. 2007 May; 148(5):2016-26.
    View in: PubMed
    Score: 0.066
  22. Tissue kallikrein infusion prevents cardiomyocyte apoptosis, inflammation and ventricular remodeling after myocardial infarction. Regul Pept. 2007 Apr 05; 140(1-2):12-20.
    View in: PubMed
    Score: 0.065
  23. Tissue kallikrein protects against pressure overload-induced cardiac hypertrophy through kinin B2 receptor and glycogen synthase kinase-3beta activation. Cardiovasc Res. 2007 Jan 01; 73(1):130-42.
    View in: PubMed
    Score: 0.064
  24. Reversal of renal fibrosis, inflammation, and glomerular hypertrophy by kallikrein gene delivery. Hum Gene Ther. 2006 May; 17(5):545-55.
    View in: PubMed
    Score: 0.062
  25. Kallikrein/kinin protects against gentamicin-induced nephrotoxicity by inhibition of inflammation and apoptosis. Nephrol Dial Transplant. 2006 Mar; 21(3):624-33.
    View in: PubMed
    Score: 0.061
  26. Tissue kallikrein attenuates salt-induced renal fibrosis by inhibition of oxidative stress. Kidney Int. 2004 Aug; 66(2):722-32.
    View in: PubMed
    Score: 0.055
  27. Circulating tissue kallikrein levels correlate with severity of carotid atherosclerosis. Arterioscler Thromb Vasc Biol. 2004 Jun; 24(6):1104-10.
    View in: PubMed
    Score: 0.054
  28. Gene therapy with human tissue kallikrein reduces hypertension and hyperinsulinemia in fructose-induced hypertensive rats. Hypertension. 2003 Nov; 42(5):1026-33.
    View in: PubMed
    Score: 0.052
  29. Reversal of angiogenic growth factor upregulation by revascularization of lower limb ischemia. Circulation. 2002 Jan 01; 105(1):67-72.
    View in: PubMed
    Score: 0.046
  30. Adenovirus-mediated gene transfer for cardiovascular and renal diseases. Methods Enzymol. 2002; 346:247-63.
    View in: PubMed
    Score: 0.046
  31. A synthetic tissue kallikrein inhibitor suppresses cancer cell invasiveness. Am J Pathol. 2001 Nov; 159(5):1797-805.
    View in: PubMed
    Score: 0.046
  32. A positively charged loop on the surface of kallistatin functions to enhance tissue kallikrein inhibition by acting as a secondary binding site for kallikrein. J Biol Chem. 2000 Dec 22; 275(51):40371-7.
    View in: PubMed
    Score: 0.043
  33. Roles of the P1, P2, and P3 residues in determining inhibitory specificity of kallistatin toward human tissue kallikrein. J Biol Chem. 2000 Dec 08; 275(49):38457-66.
    View in: PubMed
    Score: 0.043
  34. Bradykinin B(1) receptor mediates inhibition of neointima formation in rat artery after balloon angioplasty. Hypertension. 2000 Sep; 36(3):364-70.
    View in: PubMed
    Score: 0.042
  35. Human tissue kallikrein gene delivery attenuates hypertension, renal injury, and cardiac remodeling in chronic renal failure. Kidney Int. 2000 Aug; 58(2):730-9.
    View in: PubMed
    Score: 0.042
  36. Reactive-site specificity of human kallistatin toward tissue kallikrein probed by site-directed mutagenesis. Biochim Biophys Acta. 2000 Jun 15; 1479(1-2):237-46.
    View in: PubMed
    Score: 0.041
  37. Kallikrein-binding protein is induced by growth hormone in the dwarf rat. FASEB J. 1999 Oct; 13(13):1839-44.
    View in: PubMed
    Score: 0.039
  38. Human tissue kallikrein attenuates hypertension and secretes into circulation and urine after intramuscular gene delivery in hypertensive rats. Clin Exp Hypertens. 1999 Oct; 21(7):1145-60.
    View in: PubMed
    Score: 0.039
  39. DNA polymorphisms in the 5'-flanking region of the human tissue kallikrein gene. Hum Genet. 1997 Jun; 99(6):727-34.
    View in: PubMed
    Score: 0.034
  40. Kallikrein gene therapy: a new strategy for hypertensive diseases. Immunopharmacology. 1997 Jun; 36(2-3):229-36.
    View in: PubMed
    Score: 0.034
  41. Tissue kallikrein inhibitors in mammals. Immunopharmacology. 1996 May; 32(1-3):67-72.
    View in: PubMed
    Score: 0.031
  42. High level expression of human tissue kallikrein in the circulation induces hypotension in transgenic mice. Immunopharmacology. 1996 May; 32(1-3):105-7.
    View in: PubMed
    Score: 0.031
  43. Purification and characterization of recombinant tissue kallikrein from Escherichia coli and yeast. Biochem J. 1991 May 15; 276 ( Pt 1):63-71.
    View in: PubMed
    Score: 0.022
  44. A major difference of kallikrein-binding protein in spontaneously hypertensive versus normotensive rats. J Hypertens. 1988 Jul; 6(7):551-7.
    View in: PubMed
    Score: 0.018
  45. Kallikrein gene transfer protects against ischemic stroke by promoting glial cell migration and inhibiting apoptosis. Hypertension. 2004 Feb; 43(2):452-9.
    View in: PubMed
    Score: 0.013
  46. Adenovirus-mediated kallikrein gene transfer inhibits neointima formation via increased production of nitric oxide in rat artery. Immunopharmacology. 1999 Oct 15; 44(1-2):137-43.
    View in: PubMed
    Score: 0.010
  47. Localization and expression of tissue kallikrein and kallistatin in human blood vessels. J Histochem Cytochem. 1999 Feb; 47(2):221-8.
    View in: PubMed
    Score: 0.009
  48. Tissue-specific expression and promoter analyses of the human tissue kallikrein gene in transgenic mice. Biochem J. 1997 Jul 01; 325 ( Pt 1):111-6.
    View in: PubMed
    Score: 0.008
  49. Expression of human tissue kallikrein in rat salivary glands and its secretion into circulation following adenovirus-mediated gene transfer. Immunopharmacology. 1997 Jun; 36(2-3):221-7.
    View in: PubMed
    Score: 0.008
  50. Kallistatin: a novel human tissue kallikrein inhibitor. Purification, characterization, and reactive center sequence. J Biol Chem. 1992 Dec 25; 267(36):25873-80.
    View in: PubMed
    Score: 0.006
  51. Identification and characterization of a tissue kallikrein in rat skeletal muscles. Biochem J. 1987 May 01; 243(3):773-8.
    View in: PubMed
    Score: 0.004
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.